Biomarkers of aHSCT

NCT06195800 | Recruiting

• 1 other identifier: STH22343
• Study Type: observational
• Target: 15
• Locations: 1 country
• Sites: 1

Brief Summary

The underlying disease mechanisms which occur in patients with immune mediation neurological diseases, such as Multiple Sclerosis (MS), are incompletely understood. For such patients, autologous haematopoietic stem cell transplantation (aHSCT) has been increasingly used as a highly successful one-off treatment for some patients. This treatment aims to delete the faulty immune system with a course of chemotherapy and then 'reboot' the immune system using a patients' own stem cells (a cell with the unique ability of being a building block to create many different cells in the body) to stop further damage. Over the last 20 years more than 1800 patients with MS have been treated in Europe with high levels of success. It may be more successful than disease modifying treatment but unfortunately, a small portion of people do not respond to this treatment optimally and continue to accumulate disability. There is a risk of side effects, restricted largely to the time of treatment, which necessitates the need to ensure appropriate patients are treated. Whilst aHSCT is a very effective therapy, it is still in its early phase of development, is not in widespread use, and there is incomplete knowledge regarding how it works and importantly, why it does not work in some patients, and how to monitor response to treatment. Unfortunately, there is no way of detecting which patients will, and will not, benefit from the different treatments available or a way of monitoring the immune system to ensure further treatment is provided before irreversible damage occurs. This study will investigate the immune system which is found in the fluid surrounding the brain and spinal cord, blood and stool of patients undergoing aHSCT and compare it to those receiving disease modifying treatment. This study will therefore further the understanding of biomarkers of aHSCT to develop an awareness of how it can be refined, may improve monitoring of patients following treatment and permit the development of markers which can predict potential treatment success or failure before patients are exposed to the risks.

Conditions

Multiple Sclerosis, Relapsing-Remitting

Keywords

multiple sclerosis; aHSCT; Autologous haematopoetic stem cell transplantation

Outcome Measures

Primary Outcomes (2)

• Quantitatively and qualitatively characterise the immune profile of the stem cells, blood, cerebrospinal fluid (CSF) and the microbiome pre and post treatment.

  Phenotype profiling of stem cells, cells in blood and CSF using multi-parameter flow cytometry. Profile the gut microbiome using 16S rRNA sequencing and flow cytometric analysis.

  24 months

• Perform single cell RNA sequencing (scRNA-Seq) on paired CSF and blood pre and post treatment.

  Profiling of T cell receptor and B cell receptor repertoire diversity and clonality

  24 months

Secondary Outcomes (7)

• Characterisation of the regeneration of mucosal cell immunity and the reconstitution of pathogen specific immunity following aHSCT by scRNA-Seq on nasopharyngeal swabs and mucosal strips.

  24 months

• Evaluate immunological disease response and the duration of response to aHSCT according to expanded disability status scale score (EDSS)

  24 months

• Evaluate immunological disease response and the duration of response to aHSCT according to low contrast visual acuity (LCLA)

  24 months

• Evaluate immunological disease response and the duration of response to aHSCT according to multiple sclerosis functional composite score (MSFC)

  24 months

• Evaluate immunological disease response and the duration of response to aHSCT according to short form 36 (SF-36)

  24 months

Study Arms (2)

Patients treated with aHSCT

Patients with aggressive disease treated with autologous haematopoetic stem cell transplantation.

Patients treated with disease modifying treatment

Patients with aggressive disease treated with high efficacy disease modifying treatment

Eligibility Criteria

• Age: 16 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Outpatients who are attending the Sheffield (UK) transplant clinic for neurological disease.

You may qualify if:

• Diagnosis of a immune mediated neurological disease according to disease specific criteria (active treatment arm) or diagnosis of relapsing remitting multiple sclerosis (control arm).
• Treatment with autologous haematopoetic stem cell transplantation (active treatment arm) or high efficacy disease modifying treatment (control arm).
• Willing to provide biological samples for analysis and undergo clinical assessments for the duration of follow up.
• Able to understand English and provide informed consent.

You may not qualify if:

• \. Inability to provide informed consent.

Sponsors & Collaborators

• Sheffield Teaching Hospitals NHS Foundation Trust: lead
• Sheffield Hospitals Charity: collaborator
• Nottingham Trent University: collaborator
• University of Sheffield: collaborator

Study Sites (1)

Sheffield Teaching Hospitals NHS Foundation Trust

Sheffield, England, S10 2JF, United Kingdom

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Blood Stem cells Stool/microbiome Mucosal Cerebrospinal fluid

MeSH Terms

Conditions

Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases

Study Officials

• Gavin Brittain, MBBS, MRCP

  Sheffield Teaching Hospitals NHS Foundation Trust and The University of Sheffield

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Gavin Brittain, MBBS, MRCP

CONTACT

+44114 271 1900; gavin.brittain@sheffield.ac.uk

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 13, 2023
• First Posted: January 8, 2024
• Study Start: August 9, 2023
• Primary Completion (Estimated): August 9, 2026
• Study Completion (Estimated): August 9, 2026
• Last Updated: January 8, 2024

Record last verified: 2024-01

Locations

GB (1)